Creabilis Announces Start of Phase IIb Trial of TrkA Kinase Inhibitor CT327 in ... - PR Newswire (press release)

Creabilis Announces Start of Phase IIb legal proceeding of TrkA Kinase matter CT327 in ... Pr Newswire (press release) Creabilis SA, a European biotechnology company specialising in the development of treatments for dermatology, inflammation and pain, today announced the start of the Phase IIb global clinical trial of its lead product CT327 in patients with disease of the skin ... and more » Link To Article